Trials / Completed
CompletedNCT01776554
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 662 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Accepted
Summary
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adjuvanted H5N1 pandemic influenza vaccine | Comparison of two doses of aH5N1c vaccine |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-06-01
- Completion
- 2014-06-01
- First posted
- 2013-01-28
- Last updated
- 2019-01-16
- Results posted
- 2015-04-20
Locations
12 sites across 2 countries: United States, Thailand
Source: ClinicalTrials.gov record NCT01776554. Inclusion in this directory is not an endorsement.